A Trial of Lopinavir–Ritonavir in Covid-19

To the Editor: After a review of the findings of Cao et al. (published in the Journal online on March 18), 1 many clinicians are abandoning the use of lopinavir–ritonavir for the treatment of Covid-19. We consider this action to be premature. It is crucial to realize that although this trial did not show that the time until clinical improvement was meaningfully better than standard care among patients with severe Covid-19 who received lopinavir–ritonavir, the trial was statistically underpowered to show this outcome. In addition, the analyses of secondary outcomes (which still require confirmation) suggested that lopinavir–ritonavir may be associated with . . .